{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=37",
    "query": {
      "intervention": "A PROTEIN level",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 1384,
    "total_pages": 139,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T02:37:18.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00203996",
      "title": "Polycystic Ovary Syndrome (PCOS) and Sleep Apnea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "continuous positive airway pressure (CPAP)",
          "type": "DEVICE"
        },
        {
          "name": "depot leuprolide plus estrogen/progestin replacement",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "REM frag",
          "type": "PROCEDURE"
        },
        {
          "name": "SWS supp",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 37,
      "start_date": "2003-09",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00203996"
    },
    {
      "nct_id": "NCT06642662",
      "title": "Precision Medicine in the CICU: Identifying Proteomic Biomarkers",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Heart Disease"
      ],
      "interventions": [
        {
          "name": "Somascan 5.0",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Days",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "2 Days to 5 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-04-15",
      "completion_date": "2027-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06642662"
    },
    {
      "nct_id": "NCT00562640",
      "title": "Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2007-10-16",
      "completion_date": "2021-08-03",
      "has_results": true,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00562640"
    },
    {
      "nct_id": "NCT01176474",
      "title": "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "NY-ESO-1 157-165 (165V)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "gp100:280-288 (288V)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA 51 vegetable grade (VG)",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Apheresis Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2010-08-13",
      "completion_date": "2023-01-06",
      "has_results": false,
      "last_update_posted_date": "2023-07-19",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01176474"
    },
    {
      "nct_id": "NCT06698250",
      "title": "Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anwaar Saeed",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-12-18",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 3,
      "location_summary": "Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06698250"
    },
    {
      "nct_id": "NCT00250718",
      "title": "Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "VP-16",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2004-10",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-08-03",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00250718"
    },
    {
      "nct_id": "NCT06619860",
      "title": "Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Peripheral Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "VX-993",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to pregabalin)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to VX-993)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 300,
      "start_date": "2024-10-18",
      "completion_date": "2027-04-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 25,
      "location_summary": "Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619860"
    },
    {
      "nct_id": "NCT06665165",
      "title": "AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ALS"
      ],
      "interventions": [
        {
          "name": "AMX0114",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amylyx Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-04-07",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06665165"
    },
    {
      "nct_id": "NCT03324399",
      "title": "A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "ALS"
      ],
      "interventions": [
        {
          "name": "probiotic",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Avera McKennan Hospital & University Health Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2017-06-01",
      "completion_date": "2019-06-26",
      "has_results": false,
      "last_update_posted_date": "2019-07-02",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03324399"
    },
    {
      "nct_id": "NCT01025193",
      "title": "Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Desensitization"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2010-02",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-10-18T02:37:18.004Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01025193"
    }
  ]
}